Senseonics begins U.S. commercialization of Eversense CGM system
Senseonics Holdings announced that the Eversense CGM System is now available at trained clinics across the U.S. and physicians have begun sensor placements with patients. Concurrently, the company reported that its first commercial payer, Horizon Blue Cross Blue Shield of New Jersey and Horizon Healthcare of New Jersey, has added coverage of the Eversense System to its Medical Policy. Since receiving FDA approval for the Eversense System, we have experienced tremendous support and interest from physicians and their patients," said Tim Goodnow, President and CEO of Senseonics. "We are thrilled that clinics and users can now benefit from Eversense, and we're also pleased to receive our first medical policy coverage, clearing the way so more people with diabetes can access this important tool for helping ease the burden of managing diabetes."